Anne‐Charlotte de Gouville
GlaxoSmithKline (France)(FR)John Wiley & Sons (United States)(US)
Publications by Year
Research Areas
TGF-β signaling in diseases, Liver physiology and pathology, Pharmacology and Obesity Treatment, Diabetes, Cardiovascular Risks, and Lipoproteins, Protein Kinase Regulation and GTPase Signaling
Most-Cited Works
- → Expression of connective tissue growth factor in experimental rat and human liver fibrosis(1999)324 cited
- → Identification of 1,5-Naphthyridine Derivatives as a Novel Series of Potent and Selective TGF-β Type I Receptor Inhibitors(2004)219 cited
- → Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosis(2005)164 cited
- → Discovery of 4-{4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): A Potent, Selective, and Orally Active Transforming Growth Factor-β Type I Receptor Inhibitor(2006)102 cited
- → Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients(2015)57 cited
- → Inhibition of ALK5 as a New Approach to Treat Liver Fibrotic Diseases(2006)30 cited
- → Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist(2015)25 cited
- → A Randomized, Placebo‐Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High‐Density Lipoprotein Cholesterol in Subjects With Dyslipidemia(2019)11 cited
- → Issue Information(2019)1 cited